Trastuzumab antibody | AbD18018_hIgG1
A microtiter plate was coated overnight with trastuzumab at a concentration of 0.5 µg/ml. After washing and blocking with PBST+5% BSA, Human Anti-Trastuzumab Antibody clone AbD18018_hIgG1 (HCA177) in PBST + 10% Human Serum was added. Detection was performed using HRP conjugated trastuzumab at a concentration of 2 µg/ml in HISPEC Assay Diluent (BUF049A) and QuantaBlu Fluorogenic Peroxidase Substrate.
A microtiter plate was coated overnight with Human Anti-Trastuzumab Antibody, clone AbD16712 (HCA166) (black) and Human Anti-Trastuzumab Antibody, clone AbD18141 (HCA169) (red) at a concentration of 1 µg/ml. After washing and blocking with PBST+5% BSA, 10% Human Serum was added spiked with increasing concentrations of trastuzumab. Detection was performed using HRP conjugated Human Anti-Trastuzumab Antibody, clone AbD18018_hIgG1 (HCA177P) at a concentration of 2 µg/ml in HISPEC Assay Diluent (BUF049A) and QuantaBlu Fluorogenic Peroxidase Substrate.
A microtiter plate was coated overnight with various antigens at a concentration of 5 μg/ml. After washing and blocking with PBST + 5% milk powder, detection was performed using HRP conjugated Human Anti-Trastuzumab Antibody, clone AbD18018_hIgG1 (HCA177P) at a concentration of 1 μg/ml in HISPEC Assay Diluent (BUF049A) followed by QuantaBlu Fluorogenic Peroxidase Substrate.
Human anti Trastuzumab:HRP
Anti-trastuzumab antibody is a recombinant, neutralizing, high affinity anti-idiotypic antibody in fully human immunoglobulin format for bioanalytical method development. It can be used as the detection antibody in a PK bridging ELISA and as a reference standard in an ADA bridging ELISA.
Human anti Trastuzumab
Anti-trastuzumab antibody is a recombinant, neutralizing, high affinity anti-idiotypic antibody in fully human immunoglobulin format for bioanalytical method development. It can be used as the detection antibody in a PK bridging ELISA and as a reference standard in an ADA bridging ELISA.
- Product Type
- Monoclonal Antibody
- Clone
- AbD18018_hIgG1
- Isotype
- IgG1
| Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|
| HCA177P | E | 0.1 mg |
|
|
| HCA177 | E | 0.1 mg |
|
|
| HCA177G | E | 1 mg |
|
Human Anti-Trastuzumab Antibody, clone AbD18018_hIgG1, is a paratope specific, high affinity, anti-idiotypic antibody that specifically recognizes the monoclonal antibody drug trastuzumab and inhibits it binding to its target. The antibody can be used to measure the levels of trastuzumab and biosimilar products in bioanalytical assays.
Clone AbD18018_hIgG1 is a fully human recombinant monoclonal antibody with IgG1 isotype and is suitable as a reference standard in an anti-drug antibody (ADA) assay. Additionally the antibody can be used to develop a pharmacokinetic (PK) bridging assay to measure free drug in preclinical research and clinical trials using patient sera. This antibody, in full immunoglobulin format and conjugated to HRP, is recommended as the detection antibody, paired with antibody clone AbD16712 (HCA166) or clone AbD18141 (HCA169), both monovalent Fab format, as the capture antibody.
This clone is also available in IgG4 isotype format (HCA270) in order to offer assay developers increased flexibility in assay design. When used as an ELISA detection antibody, a secondary anti-human IgG4 antibody is required, which can be labeled according to the needs of the user's preferred assay platform.
Trastuzumab, also known as Herceptin, is a drug used in the treatment of HER2 positive breast cancer and other HER2 over-expressing cancers including HER2-positive metastatic cancers of the gastrointestinal tract. Trastuzumab binds to the HER2 (or c-erbB2) proto-oncogene, an EGF receptor-like protein found on 20-30% of breast cancer cells. The binding leads to antibody mediated (complement mediated) killing of the HER2 positive cells.
View a summary of all Anti-Trastuzumab Antibodies
Clone AbD18018_hIgG1 is a fully human recombinant monoclonal antibody with IgG1 isotype and is suitable as a reference standard in an anti-drug antibody (ADA) assay. Additionally the antibody can be used to develop a pharmacokinetic (PK) bridging assay to measure free drug in preclinical research and clinical trials using patient sera. This antibody, in full immunoglobulin format and conjugated to HRP, is recommended as the detection antibody, paired with antibody clone AbD16712 (HCA166) or clone AbD18141 (HCA169), both monovalent Fab format, as the capture antibody.
This clone is also available in IgG4 isotype format (HCA270) in order to offer assay developers increased flexibility in assay design. When used as an ELISA detection antibody, a secondary anti-human IgG4 antibody is required, which can be labeled according to the needs of the user's preferred assay platform.
Trastuzumab, also known as Herceptin, is a drug used in the treatment of HER2 positive breast cancer and other HER2 over-expressing cancers including HER2-positive metastatic cancers of the gastrointestinal tract. Trastuzumab binds to the HER2 (or c-erbB2) proto-oncogene, an EGF receptor-like protein found on 20-30% of breast cancer cells. The binding leads to antibody mediated (complement mediated) killing of the HER2 positive cells.
View a summary of all Anti-Trastuzumab Antibodies
Product Details
- Product Form
- Human IgG1 antibody selected from the HuCAL® phage display library and expressed in a human cell line. Conjugated to horseradish peroxidase (HRP) - liquid.
- Product Form
- Human IgG1 antibody (lambda light chain) selected from the HuCAL® phage display library and expressed in a human cell line. This antibody is supplied as a liquid.
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.01% Thiomersal
- Preservative Stabilisers
- 0.01% Thiomersal
- Immunogen
- Trastuzumab
- Affinity
- The monovalent intrinsic affinity of this antibody was measured as KD=0.02 nM by real time, label-free molecular interaction analysis on immobilized trastuzumab.
- Approx. Protein Concentrations
- IgG concentration 0.1mg/ml
- Approx. Protein Concentrations
- Pack Size: 0.1 mgIgG concentration 0.5mg/mlPack Size: 1 mgIgG concentration 1.0 mg/ml
Storage Information
- Storage
- Store at -70oC.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. - Storage
- Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch.
More Information
- Acknowledgements
- Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany.
- Acknowledgements
- Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany. Herceptin is a trademark of Genentech, Inc.
- Licensed Use
- For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
- Regulatory
- For research purposes only
Applications of Trastuzumab antibody
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| ELISA | |||
| ELISA |
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
- Technical Advice
- Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
- Technical Advice
- Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
- ELISA
- This product may be used as a detection reagent in a sandwich ELISA together with HCA169 as the capture reagent.
Protocol: PK bridging ELISA to measure free drug - ELISA
- This product may be used as a detection reagent in a sandwich ELISA, when conjugated to HRP, together with HCA169 as the capture reagent.
Protocol: PK bridging ELISA to measure free drug
This antibody is fully human and can be used as a reference standard in an ADA assay. Protocol: ADA bridging ELISA
Copyright © 2020 Bio-Rad Antibodies (formerly AbD Serotec)
Useful Reagents Available
| Description | Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|---|
| Hispec Assay Diluent | BUF049A | E IY | 50 ml | ||
| Human anti Trastuzumab | HCA166 | E | 0.1 mg |
|
|
| Human anti Trastuzumab | HCA169 | E | 0.1 mg |
|
|
| Hispec Assay Diluent | BUF049A | E IY | 50 ml | ||
| Human anti Trastuzumab | HCA166 | E | 0.1 mg |
|
|
| Human anti Trastuzumab | HCA169 | E | 0.1 mg |
|
|
| LYNX Rapid HRP Antibody Conjugation Kit | LNK002P | CJ | 3 Conjugations For 400µg Antibody | ||
| Mouse anti Human IgG (Fc) CH2 Domain:HRP | MCA647P | C* E | 0.2 mg |
|
Product Specific References
References for Trastuzumab antibody
-
Bults, P. et al. (2016) LC-MS/MS-Based Monitoring of In Vivo Protein Biotransformation: Quantitative Determination of Trastuzumab and Its Deamidation Products in Human Plasma.
Anal Chem. 88 (3): 1871-7. -
Harth, S. et al. (2019) Generation by phage display and characterization of drug-target complex-specific antibodies for pharmacokinetic analysis of biotherapeutics.
MAbs. 11 (1): 178-190. -
Iwamoto, N. et al. (2018) Antibody drug quantitation in coexistence with anti-drug antibodies on nSMOL bioanalysis.
Anal Biochem. 540-541: 30-7.
